



JP/1/4

Attorney's Docket No.: 1770-300US-1 – VC/dm

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jean-Pierre Julien et al.
Serial No.: 10/788,478
Filed: March 1, 2004
For: A NEW THERAPY FOR STROKE

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97 and 1.98

Assistant Commissioner for Patents
Alexandria, Virginia 22313-1450
U.S.A.

Sir:

Submitted herewith on form PTO/SB/08A/B is a listing of documents known to applicants in order to comply with applicant's duty of disclosure pursuant to 37 C.F.R. § 1.56. Copies of the listed documents are also being submitted herewith to comply with the provisions of 37 C.F.R. § 1.97 and 1.98, with copies of English translations of non-English language references or of the pertinent portions thereof, if such translations are readily available. If applicable, English copies of foreign search reports citing at least some of the documents herein listed on PTO/SB/08A/B are also enclosed.

The references included herewith have been cited in the specification of the instant application.

The submission of any document which is not a statutory bar is not intended as an admission that any or all documents constitute prior art against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove as a competent reference any

document which is determined to be a prima facie prior art reference against the claims of the present application.


Statement of relevancy

The listed document is being submitted either in compliance with 37 C.F.R. 197(b), within three (3) months of the filing date of a national application or of the date of entry of the national stage in an international application; or pursuant to 37 C.F.R. §1.97(e)(1), within three (3) months from the date of an office action or of a search report issued in a foreign counterpart application citing each of the documents contained in the present statement; or pursuant to 37 C.F.R. §1.97(e)(2), within three (3) months from the first knowledge of each submitted document by any individual designated in C.F.R. §1.56(c), when each such document was not cited in a communication from a foreign patent office in a counterpart foreign application.

In the case of submissions under 37 C.F.R. §1.97(e)(1) and (2), the undersigned Attorney/Agent of Record hereby certifies that the enclosed references are hereby submitted within three months (1) from the issuance of the foreign action or search report, or (2) from said first knowledge, respectively.

The Commissioner is hereby authorized to charge the amount of \$180.00 to our Deposit Account Number 19-5113 to cover payment of Submission of an Information Disclosure Statement as prescribed in 37 C.F.R. 1.17(p) and any additional fees that may be required, or credit any overpayment (file number 1770-300US-1).

Respectfully submitted,




Valérie Carrier

Registration No. 56,011

May 27, 2004

OGILVY RENAULT
1981 McGill College, Suite 1600
Montréal (Québec) H3A 2Y3
CANADA
Tel.: (514) 847-4253

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/788,478		
		Filing Date	March 1, 2004		
		First Named Inventor	Jean-Pierre Julien		
		Art Unit			
Sheet	2	of	4	Examiner Name	
				Attorney Docket Number	1770-300US-1 VC/dm

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		BEAULIEU, J.M. et al., "Induction of Peripherin Expression in Subsets of Brain Neurons After Lesion Injury or Cerebral Ischemia", Brain.Res. (2002) 946, 153-161	
		BENSIMON, G. et al., "A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis", N. Eng. J. Med. (1994) 330, 585-591	
		CANO-ABAD, M.F. et al., "Calcium Entry Through L-type Calcium Channels Causes Mitochondrial Disruption and Chromaffin Cell Death", J. Biol. Chem. (2001) 43, 39695-39704	
		CHEN, M. et al., "Minocycline Inhibits Caspase-1 and Caspase-3 Expression and Delays Mortality in a Transgenic Mouse Model of Huntington Disease", Nat. Med. (2000) 6, 797-801	
		ROGERS, D.C. et al., "Behavioral and Functional Analysis of Mouse Phenotype: SHIRPA, a Proposed Protocol for Comprehensive Phenotype Assessment", Mammalian Genome (1997) 8, 711-713	
		ROGERS, D.C. et al., "Use of SHIRPA and Discriminant Analysis to Characterise Marked Differences in the Behavioural Phenotype of Six Inbred Mouse Strains", Behav. Brain Res. (1999) 105, 207-217	
		DERESKI, M.O. et al., "The Heterogeneous Temporal Evolution of Focal Ischemia Neuronal Damage in the Rat", Acta Neuropathol. (1993) 85, 327-333	
		DIRNAGL, U. et al., "Pathobiology of Ischaemic Stroke: An Integrated View", Trends Neurosci. (1999) 22, 391-397	
		DU, Y. et al., "Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease", Proc. Natl. Acad. Sci. (2001) 98, 14669-14674	
		GOLUB, L.M. et al., "Tetracyclines Inhibit Connective Tissue Breakdown by Multiple Non-Antimicrobial Mechanisms", Adv. Dent. Res. (1998) 12, 12-26	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/788,478
				Filing Date	March 1, 2004
				First Named Inventor	Jean-Pierre Julien
				Art Unit	
				Examiner Name	
Sheet	3	of	4	Attorney Docket Number	1770-300US-1 VC/dm

		GOULDEN, V. et al., "Safety of Long-Term High-Dose Minocycline in the Treatment of Acne", Br. J. Dermatol. (1996) 134, 693-695	
		GURNEY, M.E. et al., "Benefit of Vitamin E, Riluzole, and Gabapentin in a Transgenic Model of Familial Amyotrophic Lateral Sclerosis", Ann. Neurol. (1996) 39, 147-157	
		HACKE, W. et al., "Thrombolysis in Acute Ischemic Stroke: Controlled Trials and Clinical Experience", Neurology (1999) 53, S3-14	
		JULIEN, J.P., "Amyotrophic Lateral Sclerosis: Unfolding the Toxicity of the Misfolded", Cell (2001) 104, 581-591	
		KORENKOV, A.I. et al., "Treatment with Nimodipine or Mannitol Reduces Programmed Cell Death and Infarct Size Following Focal Cerebral Ischemia", Neurosurg. Rev. (2000) 23, 145-150	
		KRIZ J. et al., "Differential Effects of Dihydropyridine Calcium Channel Blockers in Kainic Acid-Induced Experimental Seizures in Rats", Epilepsy Res. (2003) 52, 215-225	
		KRIZ, J. et al., "Efficient Three-Drug Cocktail for Disease Induced by Mutant Superoxide Dismutase", Ann. Neurol. (2003) 53, 429-436	
		KRIZ, J. et al., "Minocycline Slows Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis", Neurobiol. Dis. (2002) 10, 268-278	
		LO, E.H. et al., "Mechanisms, Challenges and Opportunities in Stroke", Nat. Rev. Neurosci. (2003) 4, 399-415	
		MARTIN, D. et al., "The Neuroprotective Agent Riluzole Inhibits Release of Glutamate and Aspartate from Slices of Hippocampal Area CA1", Eur. J. Pharmacol. (1993) 250, 473-476	
		SINGH. B. "The Mechanism of Action of Calcium Antagonists Relative to Their Clinical Applications", Br. J. Clin. Pharmacol. (1986) 21, 109-121	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/788,478	
			Filing Date	March 1, 2004	
			First Named Inventor	Jean-Pierre Julien	
			Art Unit		
Examiner Name					
Sheet	4	of	4	Attorney Docket Number	1770-300US-1 VC/dm

		The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, "Tissue Plasminogen Activator For Acute Ischemic Stroke", New Eng. J. Med. (1995) 333, 1581-1587	
		TIKKA, T. et al., "Minocycline, a Tetracycline Derivative, Is Neuroprotective Against Excitotoxicity by Inhaling Activation and Proliferation of Microglia", J. Neurosci. (2001) 21, 2580-2588	
		VAN DEN BOSCH, L. et al., "Minocycline Delays Disease Onset and Mortality in a Transgenic Model of ALS", NeuroReport (2002) 13, 1067-1070	
		YRJANHEIKKI, J. et al., "A tetracycline Derivative, Minocycline, Reduces Inflammation and Protects Against Focal Cerebral Ischemia with a Wide Therapeutic Window", Proc. Natl. Acad. Sci. (1999) 96, 13496-13500	
		YRJANHEIKKI, J. et al., "Tetracyclines Inhibit Microglial Activation and are Neuroprotective in Global Brain Ischemia", Proc. Natl. Acad. Sci. (1998) 95, 15769-15774	
		ZHU, S. et al., "Minocycline Inhibits Cytochrome c Release and Delays Progression of Amyotrophic Lateral Sclerosis in Mice", Nature (2002) 417, 74-78	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.